GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (2)
  • Ichikado, Kazuya  (2)
  • Nakano, Aiko  (2)
Material
Publisher
  • Wiley  (2)
Person/Organisation
Language
Years
  • 1
    Online Resource
    Online Resource
    The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events
    Wiley ; 2020
    In:  Asia-Pacific Journal of Clinical Oncology Vol. 16, No. 2 ( 2020-04)
    Details
    In: Asia-Pacific Journal of Clinical Oncology, Wiley, Vol. 16, No. 2 ( 2020-04)
    Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR‐TKI because of adverse events provides a benefit. Methods This retrospective study evaluated data from 22 patients with EGFR mutation‐positive NSCLC who received at least two EGFR‐TKIs that were switched because of adverse events (March 2011 to September 2017). Progression‐free survival 2 (PFS2) was defined as the time from starting of the first EGFR‐TKI treatment to disease progression during the second EGFR‐TKI treatment. Results Seventeen patients received gefitinib as the first EGFR‐TKI treatment, while four patients received afatinib and one patient received erlotinib. The median time to failure of the first EGFR‐TKI treatment was 1.6 months. The EGFR‐TKIs were switched because of hepatotoxicity ( n  = 16), interstitial lung disease ( n  = 3), and other reasons ( n  = 3). The median washout period was 1.1 months. Seventeen patients received erlotinib as the second EGFR‐TKI treatment, while three patients received gefitinib and two patients received afatinib. The median PFS for the second EGFR‐TKI treatment was 15.2 months. The median PFS2 was 17.7 months and the median overall survival was 32.8 months. Conclusions Switching EGFR‐TKIs because of adverse events provided a clinical benefit for patients with EGFR mutation‐positive NSCLC. Appropriate judgment regarding switching from one EGFR‐TKI to another may improve the performance status and prognosis of patients with EGFR mutation‐positive NSCLC.
    Type of Medium: Online Resource
    ISSN: 1743-7555 , 1743-7563
    URL: Issue
    URL: Article
    DOI: 10.1111/ajco.v16.2
    DOI: 10.1111/ajco.13103
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2187409-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors
    Wiley ; 2019
    In:  Thoracic Cancer Vol. 10, No. 12 ( 2019-12), p. 2259-2266
    Details
    In: Thoracic Cancer, Wiley, Vol. 10, No. 12 ( 2019-12), p. 2259-2266
    Abstract: The use of baseline tumor burden (TB) as a prognostic factor for non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) and associations between TB and other prognostic biomarkers remain unclear. In this study, we investigated the association between TB and survival in NSCLC patients treated with ICIs in comparison with other biomarkers. Methods We retrospectively evaluated 83 NSCLC patients with ICIs administered between February 2016 and December 2018. TB was measured as the sum of the unidimensional diameters of up to five target lesions. Results The median observation period was 14.2 months. A total of 42 patients died during the follow‐up. Univariate Cox regression analysis showed that baseline TB was associated with OS. Cox regression analysis adjusted for Eastern Cooperative Oncology Group performance status (ECOG PS) alone or with addition of programmed cell death ligand 1 expression and treatment line showed that TB was a prognostic factor for OS. Using time‐dependent receiver operating characteristic curve analysis, the optimal TB cutoff for predicting OS was 12 cm, and patients were divided into a high TB group ( n = 21) and a low TB group ( n = 62). The low TB group achieved significantly longer OS than the high TB group (median OS: 18.5 months, [95% CI = 11.7‐not reached] vs. 2.3 months [95% CI = 1.3–2.9] , P 〈  0.001). Conclusion TB is a useful, clinically measurable prognostic factor of survival in NSCLC patients treated with ICIs.
    Type of Medium: Online Resource
    ISSN: 1759-7706 , 1759-7714
    URL: Issue
    URL: Article
    DOI: 10.1111/tca.v10.12
    DOI: 10.1111/1759-7714.13214
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 2559245-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...